BRPI0409322B8 - método para preparar um conjugado de insulina-polímero - Google Patents

método para preparar um conjugado de insulina-polímero

Info

Publication number
BRPI0409322B8
BRPI0409322B8 BRPI0409322A BRPI0409322A BRPI0409322B8 BR PI0409322 B8 BRPI0409322 B8 BR PI0409322B8 BR PI0409322 A BRPI0409322 A BR PI0409322A BR PI0409322 A BRPI0409322 A BR PI0409322A BR PI0409322 B8 BRPI0409322 B8 BR PI0409322B8
Authority
BR
Brazil
Prior art keywords
polymer
insulin
protein
conjugate
preparing
Prior art date
Application number
BRPI0409322A
Other languages
English (en)
Inventor
Lewis Danny
M Campbell Kathleen
Hinds Kenneth
Schmidt Paul
Original Assignee
Antriabio Inc
Pr Pharmaceuticals Inc
Rezolute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Antriabio Inc, Pr Pharmaceuticals Inc, Rezolute Inc filed Critical Antriabio Inc
Priority to BR122016021907A priority Critical patent/BR122016021907B8/pt
Publication of BRPI0409322A publication Critical patent/BRPI0409322A/pt
Publication of BRPI0409322B1 publication Critical patent/BRPI0409322B1/pt
Publication of BRPI0409322B8 publication Critical patent/BRPI0409322B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

"método para preparação de conjugados de proteína específicos de local". a invenção refere-se a um método de etapa única, para preparar rapidamente e eficientemente conjugados de proteína-polímero, inclusive um conjugado de insulina-polímero. de acordo com o método da presente invenção, uma proteína e polímero hidrofílico são postos em contato na presença de pelo menos um solvente orgânico e pelo menos um quelador metálico, sob condições que promovem a formação de um conjugado da proteína e polímero. desse modo, a invenção está voltada para a modificação específica de local de proteínas selecionadas, tal como insulina, com poli(etilenoglicol) no resíduo pheb1. a invenção também põe à disposição uma formulação farmacêutica para encapsular o conjugado em um polímero biodegradável.
BRPI0409322A 2003-04-11 2004-04-08 método para preparar um conjugado de insulina-polímero BRPI0409322B8 (pt)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BR122016021907A BR122016021907B8 (pt) 2003-04-11 2004-04-08 conjugado de insulina-peg, microesfera de poli(lactídioco-glicolídio), formulação de liberação de droga, e uso

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46236403P 2003-04-11 2003-04-11
PCT/US2004/010995 WO2004091494A2 (en) 2003-04-11 2004-04-08 Method for preparation of site-specific protein conjugates

Publications (3)

Publication Number Publication Date
BRPI0409322A BRPI0409322A (pt) 2006-04-25
BRPI0409322B1 BRPI0409322B1 (pt) 2017-02-07
BRPI0409322B8 true BRPI0409322B8 (pt) 2021-05-25

Family

ID=33299938

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0409322A BRPI0409322B8 (pt) 2003-04-11 2004-04-08 método para preparar um conjugado de insulina-polímero
BR122016021907A BR122016021907B8 (pt) 2003-04-11 2004-04-08 conjugado de insulina-peg, microesfera de poli(lactídioco-glicolídio), formulação de liberação de droga, e uso

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR122016021907A BR122016021907B8 (pt) 2003-04-11 2004-04-08 conjugado de insulina-peg, microesfera de poli(lactídioco-glicolídio), formulação de liberação de droga, e uso

Country Status (9)

Country Link
US (2) US9040664B2 (pt)
EP (2) EP1613272B1 (pt)
JP (3) JP2006522816A (pt)
CN (2) CN101514223B (pt)
AU (2) AU2004229461A1 (pt)
BR (2) BRPI0409322B8 (pt)
CA (2) CA3074393A1 (pt)
DK (1) DK2599502T3 (pt)
WO (1) WO2004091494A2 (pt)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0409032A (pt) 2003-04-10 2006-05-02 Pr Pharmaceuticals método para a produção de micropartìculas à base de emulsão
EP1613272B1 (en) * 2003-04-11 2013-12-18 Antriabio, Inc. Method for preparation of site-specific protein conjugates
US8871269B2 (en) 2003-07-15 2014-10-28 Evonik Corporation Method for the preparation of controlled release formulations
BRPI0412211A (pt) 2003-07-23 2006-08-22 Pr Pharmaceuticals Inc composições de liberação controlada
SI1648933T1 (sl) * 2003-07-25 2010-01-29 Conjuchem Biotechnologies Inc Dolgo delujoäś inzulinski derivat in metoda zanj
US7786213B2 (en) * 2003-10-15 2010-08-31 The Regents Of The University Of California Biomacromolecule polymer conjugates
TWI376234B (en) 2005-02-01 2012-11-11 Msd Oss Bv Conjugates of a polypeptide and an oligosaccharide
US20100166700A1 (en) * 2006-02-28 2010-07-01 Oligasis Corporation Acryloyloxyethylphosphorylcholine Containing Polymer Conjugates and Their Preparation
ES2647528T3 (es) * 2006-07-25 2017-12-22 Lipoxen Technologies Limited Polisialilación N-terminal
CA2659990C (en) * 2006-08-04 2016-03-22 Prolong Pharmaceuticals, Inc. Polyethylene glycol erythropoietin conjugates
TWI451876B (zh) 2008-06-13 2014-09-11 Lilly Co Eli 聚乙二醇化之離脯胰島素化合物
WO2010030366A2 (en) 2008-09-11 2010-03-18 Nektar Therapeutics Polymeric alpha-hydroxy aldehyde and ketone reagents and conjugation method
JP5765813B2 (ja) 2008-09-19 2015-08-19 ウェルズ ファーゴ バンク ナショナル アソシエイション 治療用ペプチドのポリマーコンジュゲート
HUE030373T2 (en) * 2009-03-20 2017-05-29 Hanmi Science Co Ltd A method for producing a site-specific conjugate of a physiologically active polypeptide
GB0905555D0 (en) * 2009-03-31 2009-05-13 Peptcell Ltd Pharmaceutical agent
US20120201873A1 (en) 2009-08-05 2012-08-09 Pieris Ag Controlled release formulations of lipocalin muteins
TW201138831A (en) * 2009-09-30 2011-11-16 Prolong Pharmaceuticals Inc Modified granulocyte colony stimulating factor (G-CSF)
US8765432B2 (en) 2009-12-18 2014-07-01 Oligasis, Llc Targeted drug phosphorylcholine polymer conjugates
US9981017B2 (en) 2010-04-02 2018-05-29 Hanmi Science Co., Ltd. Insulin conjugate using an immunoglobulin fragment
AR081066A1 (es) 2010-04-02 2012-06-06 Hanmi Holdings Co Ltd Conjugado de insulina donde se usa un fragmento de inmunoglobulina
KR20130049671A (ko) * 2011-11-04 2013-05-14 한미사이언스 주식회사 생리활성 폴리펩타이드 결합체 제조 방법
AR090281A1 (es) 2012-03-08 2014-10-29 Hanmi Science Co Ltd Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo
AR090843A1 (es) 2012-05-09 2014-12-10 Lilly Co Eli Tratamiento para diabetes comorbida con enfermedad renal cronica
US20150204857A1 (en) * 2012-08-23 2015-07-23 Stemcell Technologies Inc. Compositions and Methods for Rapid and Reversible Biomolecular Labeling
WO2015035342A2 (en) 2013-09-08 2015-03-12 Oligasis Llc Factor viii zwitterionic polymer conjugates
WO2015130963A2 (en) 2014-02-27 2015-09-03 Xenetic Biosciences, Inc. Compositions and methods for administering insulin or insulin-like protein to the brain
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
US9439864B2 (en) 2014-07-07 2016-09-13 Antriabio, Inc. Solvent extraction from biodegradable microparticles
CA2958578A1 (en) 2014-08-21 2016-02-25 The General Hospital Corporation Tumor necrosis factor superfamily and tnf-like ligand muteins and methods of preparing and using the same
JP6849590B2 (ja) 2014-10-17 2021-03-24 コディアック サイエンシーズ インコーポレイテッドＫｏｄｉａｋ Ｓｃｉｅｎｃｅｓ Ｉｎｃ． ブチリルコリンエステラーゼ両性イオン性ポリマーコンジュゲート
US10046058B2 (en) 2014-12-02 2018-08-14 Rezolute, Inc. Use of hydrophobic organic acids to increase hydrophobicity of proteins and protein conjugates
WO2016196017A1 (en) 2015-06-04 2016-12-08 Antriabio, Inc. Amine pegylation methods for the preparation of site-specific protein conjugates
WO2017117464A1 (en) 2015-12-30 2017-07-06 Kodiak Sciences Inc. Antibodies and conjugates thereof
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
DE2930542A1 (de) 1979-07-27 1981-02-12 Hoechst Ag Neue insulinderivate und verfahren zu ihrer herstellung
US5102872A (en) 1985-09-20 1992-04-07 Cetus Corporation Controlled-release formulations of interleukin-2
US5349052A (en) 1988-10-20 1994-09-20 Royal Free Hospital School Of Medicine Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor
IE912365A1 (en) 1990-07-23 1992-01-29 Zeneca Ltd Continuous release pharmaceutical compositions
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US5650234A (en) 1994-09-09 1997-07-22 Surface Engineering Technologies, Division Of Innerdyne, Inc. Electrophilic polyethylene oxides for the modification of polysaccharides, polypeptides (proteins) and surfaces
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
US5942253A (en) 1995-10-12 1999-08-24 Immunex Corporation Prolonged release of GM-CSF
DK0975334T3 (da) 1997-04-17 2004-01-19 Amgen Inc Biologisk nedbrydelige mikropartikler til langvarig frigivelse af terapeutiske midler
US6323311B1 (en) * 1999-09-22 2001-11-27 University Of Utah Research Foundation Synthesis of insulin derivatives
IL148890A0 (en) 1999-10-08 2002-09-12 Shearwater Corp Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation
US6586398B1 (en) * 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
ATE537845T1 (de) * 2000-10-31 2012-01-15 Pr Pharmaceuticals Inc Verfahren zur herstellung von formulierungen zur verbesserten abgabe von bioaktiven molekülen
AU2002239279A1 (en) 2000-11-20 2002-06-03 Pr Pharmaceuticals, Inc. Oral nanosphere delivery
KR20030097876A (ko) * 2001-05-21 2003-12-31 넥타르 테라퓨틱스 화학적으로 개질된 인슐린의 폐 투여
US6858580B2 (en) * 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
EP1613272B1 (en) * 2003-04-11 2013-12-18 Antriabio, Inc. Method for preparation of site-specific protein conjugates
GB201107664D0 (en) 2011-05-09 2011-06-22 Univ Leuven Kath Sensor for detecting liquid spilling

Also Published As

Publication number Publication date
EP1613272A2 (en) 2006-01-11
US20070083006A1 (en) 2007-04-12
EP2599502A2 (en) 2013-06-05
CA3074393A1 (en) 2004-10-28
WO2004091494A2 (en) 2004-10-28
EP1613272B1 (en) 2013-12-18
JP2010248241A (ja) 2010-11-04
WO2004091494A3 (en) 2006-02-09
JP2006522816A (ja) 2006-10-05
AU2004229461A1 (en) 2004-10-28
JP5576200B2 (ja) 2014-08-20
BRPI0409322B1 (pt) 2017-02-07
CA2521381A1 (en) 2004-10-28
EP2599502A3 (en) 2014-07-30
BRPI0409322A (pt) 2006-04-25
AU2010212312A1 (en) 2010-09-02
JP2013256498A (ja) 2013-12-26
EP2599502B1 (en) 2017-03-01
US9789196B2 (en) 2017-10-17
EP1613272A4 (en) 2010-06-16
US20150216995A1 (en) 2015-08-06
BR122016021907B1 (pt) 2018-01-09
AU2010212312B2 (en) 2012-05-17
CN1777440A (zh) 2006-05-24
US9040664B2 (en) 2015-05-26
CA2521381C (en) 2020-05-26
BR122016021907B8 (pt) 2021-07-27
CN101514223A (zh) 2009-08-26
DK2599502T3 (en) 2017-04-18
CN101514223B (zh) 2017-03-01

Similar Documents

Publication Publication Date Title
BRPI0409322B8 (pt) método para preparar um conjugado de insulina-polímero
BRPI0611872B8 (pt) reagente polimérico, conjugado, método para preparação de um conjugado e composição farmacêutica
AR009127A1 (es) Procedimiento de preparacion de nanoparticulas de metilideno malona, particulas que contienen eventualmente una o mas moleculas biologicamente activas y composiciones farmaceuticas que las contienen
BRPI0612654B8 (pt) método para conjugar um sacarídeo a uma proteína, e, conjugado sacarídeo-proteína
CY1116520T1 (el) Φαρμακοτεχνικη μορφη fulvestrant
BRPI0417341A (pt) fator ix glicopeguilado
BR0014767A (pt) Fibras de sementes de plantas e uso
DE602006007177D1 (de) Polyglutamat-aminosäure-konjugate und verfahren
BR0002276A (pt) Conjugado, composição que compreendeconjugados, composição farmacêutica, utilizaçãode um conjugado ou composição e processso paraa preparação de compostos
BRPI0309868B8 (pt) métodos de preparação de uma composição de reduzida fração conjugada inferior
BR9910333A (pt) Adesivos de cura sob demanda, módulo de janela com adesivo de cura sob demanda nele e processo para ligar dois substratos
CR7776A (es) Conjugados de polimero con antigenicidad disminuida, metodos de preparacion y usos de los mismos
BR9910481A (pt) Composição farmacêutica para comprimido de liberação não-contìnua
BRPI0416038A (pt) gel baseado em tensoativo como um veìculo injetável de liberação sustentada de droga
BRPI9809791B8 (pt) compostos imuno efetores de fosfato de aminoalquil glucosamina e composições compreendendo os mesmos
DK1317921T3 (da) Farmaceutisk sammensætning i form af en gel eller oplösning med dihydrotestosteron, fremgangsmåde til fremstilling og anvendelser heraf
BRPI0418309B8 (pt) "géis coesos de hialuronado e/ou hilano reticulados, processo para a preparação dos mesmos, bem como composições e dispositivos compreendendo os referidos géis".
CO5090836A1 (es) 3s tetrahidro 3 furanil 1s, 2r 3 / 4 aminofenil sulfonil (isobutil) [amino]1 bencil 2/(fosfonooxi)propilcarbamato de calcio
CY1110169T1 (el) Μεθοδος παρασκευης πολυμερων με χαρακτηριστικες δραστικες ομαδες απο πολυμερεις αλκοολες
BR0316310A (pt) Composições farmacêuticas tendo um veìculo modificado
BRPI0412952A (pt) composição que compreende uma matriz poliamida, processos de preparação de uma composição poliamida, processo de fabricação de um artigo e artigo
BR0315354A (pt) Misturas de polìmeros compreendendo borracha de nitrilo de baixo peso molecular
BR0015596A (pt) Método de preparação de partìculas de uma substância, e, partìculas de uma substância
ATE374598T1 (de) Mikropartikel und verfahren zur deren herstellung
BR0005191A (pt) Disposição de depósitos prevista para montagem num veìculo

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25A Requested transfer of rights approved

Owner name: ANTRIABIO, INC. (US)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: A CLASSIFICACAO ANTERIOR ERA: A61K 31/00

Ipc: A61K 38/28 (2006.01), A61K 47/48 (2006.01), A61K 9

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: A61K 47/60 (2017.01), A61K 9/50 (2006.01), A61K 38

B25A Requested transfer of rights approved
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 08/04/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 18A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2665 DE 01-02-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.